Evidence map›Paper›PMID 39516348›Full record

ArticleInternational urology and nephrology2025

Efficacy and safety of neoadjuvant chemohormonal therapy for high-risk prostate cancer treated with robot-assisted laparoscopic radical prostatectomy: a propensity score-matched analysis (the MSUG94 group).

Yuki Yokoyama, Makoto Kawase, Shin Ebara, Tomoyuki Tatenuma, Takeshi Sasaki, Yoshinori Ikehata, Akinori Nakayama, Masahiro Toide, Tatsuaki Yoneda, Kazushige Sakaguchi and 8 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuki YokoyamaDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagito, Gifu, 501-1194, Japan.
Makoto KawaseDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagito, Gifu, 501-1194, Japan. kawase.makoto.g5@f.gifu-u.ac.jp.
Shin EbaraDepartment of Urology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
Tomoyuki TatenumaDepartment of Urology, Yokohama City University, Yokohama, Japan.
Takeshi SasakiDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
Yoshinori IkehataDepartment of Urology, University of Toyama, Toyama, Japan.
Akinori NakayamaDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Masahiro ToideDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Tatsuaki YonedaDepartment of Urology, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Kazushige SakaguchiDepartment of Urology, Toranomon Hospital, Tokyo, Japan.
Jun TeishimaDepartment of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, Kobe, Japan.
Kazuhide MakiyamaDepartment of Urology, Yokohama City University, Yokohama, Japan.
Takahiro InoueDepartment of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan.
Hiroshi KitamuraDepartment of Urology, University of Toyama, Toyama, Japan.
Kazutaka SaitoDepartment of Urology, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan.
Fumitaka KogaDepartment of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Shinji UrakamiDepartment of Urology, Toranomon Hospital, Tokyo, Japan.
Takuya KoieDepartment of Urology, Gifu University Graduate School of Medicine, 1-1 Yanagito, Gifu, 501-1194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe optimal neoadjuvant regimen before radical prostatectomy (RP) in patients with high-risk (HR) prostate cancer (PCa) remains to be determined. This retrospective multicenter cohort study assessed the effectiveness and safety of neoadjuvant chemohormonal therapy (NCHT) in patients with HR-PCa undergoing robot-assisted laparoscopic radical prostatectomy (RALP).

methodsWe reviewed the datasets of 1023 subjects who underwent RALP at nine Japanese facilities between September 2012 and October 2023. The enrolled patients were divided into two groups using propensity score matching: a RALP-alone group and those who underwent NCHT followed by RALP (NCHT group). The NCHT regimen consisted of a luteinizing hormone-releasing hormone antagonist and tegafur-uracil for at least 3 months before RALP. The primary endpoint was biochemical recurrence (BCR) after RALP. The secondary endpoint was the surgical specimen pathology findings.

resultsPropensity score matching identified 139 individuals for each group. Median follow-up was 18.2 months. During follow-up, BCR was observed in 41 patients (29.5%) in the RALP-alone group and 22 patients (15.8%) in the NCHT group (p = 0.010). Pathological results showed significantly more organ-confined PCa and significantly fewer positive surgical margins or lymphovascular invasion in the NCHT group than in the RALP-alone group. The 2-yr biochemical recurrence-free survival (BRFS) was 72.7% and 74.7% in the RALP-alone and NCHT groups, respectively (p = 0.086). Two patients (1.4%) experienced grade 3 liver disorder as an NCHT-related adverse event.

conclusionThe results suggest that NCHT can safely treat HR-PCa and may reduce the incidence of BCR when combined with RALP.

Indexed as

LaparoscopyNeoadjuvant TherapyProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresAgedHumansMaleMiddle AgedPropensity ScoreRetrospective StudiesTreatment OutcomeBiochemical recurrence-free survivalHigh-risk prostate cancerLuteinizing hormone-releasing hormone antagonistNeoadjuvant chemohormonal therapyRobot-assisted laparoscopic radical prostatectomyTegafur-uracil

Identifiers

PMID39516348

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.